Survodutide: what it is and what the evidence says
A dual agonist: it activates the GLP-1 receptor and the glucagon receptor at the same time. The idea is to add the satiety signal to the increase in energy expenditure that the glucagon pathway provides.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilising stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Weight management, metabolic fatty liver disease.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
A dual glucagon and GLP-1 agonist with real and growing human evidence: after phase 2 trials in obesity and in metabolic steatohepatitis, the phase 3 SYNCHRONIZE programme has now published results in the New England Journal of Medicine and in Nature Medicine.
The limitation that matters most
It is still not approved or marketed anywhere, so any product sold under this name on the internet does not come from a regulated manufacturer. The glucagon component raises heart rate, and long-term cardiovascular safety data are lacking.
Regulatory status
Not approved. Under investigation (phase 3).
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Investigational, not approved. The glucagon component raises heart rate.
Anyone with an arrhythmia, existing heart disease or medication that already speeds up the pulse should talk to a doctor first, since that is where the glucagon arm bites.
What this page cannot give you
A reference page can take you this far. You know what Survodutide is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a diploma with a verifiable folio, a record to track how you progress, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Survodutide Once Weekly for the Treatment of Adults with Obesityhuman N Engl J Med · 2026 · PMID 42253238 →
- Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trialhuman Nat Med · 2026 · PMID 42252333 →
- Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASHhuman Hepatology · 2026 · PMID 42545725 →
- Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesityhuman Diabetes Obes Metab · 2026 · PMID 42331726 →
- A review of survodutide: a new dual acting agonistreview Minerva Endocrinol (Torino) · 2026 · PMID 41855048 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Survodutide or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Survodutide?
A dual agonist: it activates the GLP-1 receptor and the glucagon receptor at the same time. The idea is to add the satiety signal to the increase in energy expenditure that the glucagon pathway provides. It is studied within the area of metabolic.
Is there human evidence for Survodutide?
A dual glucagon and GLP-1 agonist with real and growing human evidence: after phase 2 trials in obesity and in metabolic steatohepatitis, the phase 3 SYNCHRONIZE programme has now published results in the New England Journal of Medicine and in Nature Medicine.
Is it approved by any health agency?
Not approved. Under investigation (phase 3).
What is the dose of Survodutide?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Survodutide is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.